European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- -
The European Pharmacopoeia (Ph. Eur.) Monograph 0478, (Compressi), defines the general quality, manufacturing, and testing standards for tablet preparations, including requirements for dissolution and mass uniformity. It specifies standards for various types, such as uncoated, coated, and gastro-resistant tablets, often requiring compliance with additional Ph. Eur. chapters. For the full text, see uspbpep.com
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more ICH Q4B Annex 5 - Disintegration Test General Chapter - EMA
The European Pharmacopoeia (Ph. Eur.) Monograph 0478 is the foundational quality standard for tablets intended for oral administration in Europe. Published by the European Directorate for the Quality of Medicines & HealthCare (EDQM), it establishes legally binding requirements for the definition, production, and testing of diverse tablet forms to ensure patient safety and therapeutic efficacy. 1. Scope and Definition
According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are primarily obtained by compressing uniform volumes of particles but can also be manufactured via extrusion, moulding, or freeze-drying (lyophilisation).
The monograph explicitly excludes preparations like lozenges, oral pastes, and oral gums , which are covered under separate general chapters such as Oromucosal Preparations (1807). 2. Recognized Categories of Tablets
Monograph 0478 distinguishes several specific categories, each with tailored requirements:
Uncoated Tablets: Single or multi-layer tablets without specific release-modifying excipients.
Coated Tablets: Finished with layers of resins, sugars, or polymers (film-coated) to protect the core or mask taste.
Modified-Release: Includes prolonged-release and pulsatile-release tablets designed to alter the rate or timing of drug delivery.
Gastro-Resistant: Delayed-release tablets intended to resist gastric fluid and release the active substance in the intestinal tract.
Effervescent: Formulated with carbonates to react in water and release carbon dioxide for rapid dispersion.
Orodispersible and Soluble: Tablets designed to disperse rapidly in the mouth or dissolve in water before administration. 3. Production and Quality Control Requirements
Manufacturers must implement measures to ensure tablets possess sufficient mechanical strength to withstand handling. Standardized testing includes:
Resistance to Crushing: Measured in Newtons, typically on a sample of 10 tablets to determine the force required for disruption.
Friability: Assessed via general chapter 2.9.7 to ensure tablets do not crumble or break during processing or transport.
Subdivision (Scoring): For tablets with break-marks, the efficacy of the mark is assessed by weighing subdivided parts. Not more than one out of 30 parts may fall outside 85% to 115% of the average mass. 4. Mandatory Pharmacopoeial Tests
Compliance with Monograph 0478 requires several critical laboratory tests, often cross-referencing general chapters:
Disintegration (2.9.1): Uncoated tablets must typically disintegrate within 15 minutes in water at 37°C. Coated tablets (non-film) are allowed up to 60 minutes.
Dissolution (2.9.3): Since January 2018, revised standards mandate a suitable dissolution test for immediate-release forms unless otherwise justified.
Uniformity of Dosage Units (2.9.40): Ensures each tablet in a batch contains the correct amount of active pharmaceutical ingredient (API). Summary of Standard Disintegration Times Tablet Type Max Time Allowed 15 minutes Film-coated 30 minutes Other Coated 60 minutes Soluble/Dispersible Water (15–25°C) Effervescent Water (15–25°C) Revised Ph. Eur. Chapter Tablets - gmp-compliance.org
European Pharmacopoeia (Ph. Eur.) Monograph: Tablets (0478)
The European Pharmacopoeia (Ph. Eur.) is a publication that sets standards for the quality, purity, and strength of medicines in Europe. The monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets, which are a widely used dosage form for administering medicinal products. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
Scope
This monograph applies to tablets, which are solid dosage forms containing one or more active pharmaceutical ingredients, compressed into a single unit. The monograph covers tablets that are intended for oral administration, including immediate-release, modified-release, and prolonged-release tablets.
Definition
Tablets are defined as solid dosage forms that are prepared by compressing a mixture of active pharmaceutical ingredients and excipients. The tablets must be uniform in size, shape, and weight, and must meet specific requirements for hardness, friability, and disintegration.
Requirements
The Ph. Eur. monograph for Tablets (0478) specifies the following requirements:
Test methods
The monograph specifies the test methods that must be used to evaluate tablets, including:
Conclusion
The European Pharmacopoeia (Ph. Eur.) monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets. The monograph covers a range of requirements, including appearance, average weight, uniformity of weight, hardness, friability, disintegration, and dissolution. By following these specifications, manufacturers can ensure that their tablets meet the necessary standards for quality, purity, and strength.
The European Pharmacopoeia (Ph. Eur.) Monograph 0478, titled "Tablets" (Compressi), is the central general monograph establishing the mandatory quality standards for all tablet dosage forms in Europe. It provides the legal and scientific framework for their development, production, and marketing. Core Definition & Scope
Form: Tablets are solid preparations containing a single dose of one or more active substances, typically obtained by compression.
Administration: Primarily intended for oral administration, though they can be swallowed whole, chewed, or dispersed in water.
Exclusions: This monograph does not apply to lozenges, oral pastes, or oral gums, which are covered under other sections like Oromucosal Preparations (1807). Primary Tablet Categories
The monograph distinguishes between several specialized tablet types, each with specific requirements:
Uncoated & Coated Tablets: Standard forms, with film-coated variants specified for thin polymeric layers.
Modified-Release: Designed to change the rate, place, or time of drug release (e.g., prolonged or delayed release).
Gastro-Resistant: Intended to resist gastric fluid and release substances in the intestine.
Fast-Acting: Includes Effervescent, Soluble, Dispersible, and Orodispersible tablets, most of which must meet a strict disintegration limit of 3 minutes. Key Quality Control Tests
Monograph 0478 mandates several critical tests to ensure batch-to-batch consistency:
Disintegration (2.9.1): Measures the time required for tablets to break up in a liquid medium. Standard uncoated tablets typically must disintegrate within 15 minutes. The European Pharmacopoeia (Ph
Dissolution (2.9.3): Mandatory for most solid dosage forms to confirm the active substance is released as intended.
Uniformity of Dosage Units (2.9.40): Ensures each tablet contains the correct amount of active substance, typically through Uniformity of Mass or Uniformity of Content.
Subdivision (Break-marks): Revised in Supplement 9.3, this requires that break-marks be functional. If used for fractional dosing, the subdivided parts must meet strict uniformity of mass standards (e.g., 30 parts tested; most must be within 85–115% of average mass).
Mechanical Strength: While not always mandatory for final release, tests for Friability (2.9.7) and Resistance to Crushing (2.9.8) are used during production to ensure tablets don't crumble during handling. Recent Regulatory Updates
The European Pharmacopoeia (Ph. Eur.) Monograph 0478 (Tablets/Compressi) serves as the legally binding foundational standard for all tablet dosage forms in Europe. It ensures that regardless of the manufacturer, tablets meet consistent quality, safety, and efficacy requirements through rigorous manufacturing and testing protocols. Scope and Definitions
Monograph 0478 defines tablets as solid preparations containing a single dose of one or more active substances. They are primarily produced by compressing particles but can also be made through extrusion or freeze-drying (oral lyophilisates). This general monograph covers various categories, including: Uncoated and Coated Tablets. Gastro-resistant and Modified-release Tablets. Effervescent, Soluble, and Dispersible Tablets.
Orodispersible Tablets (disintegrating in the mouth within 3 minutes). Key Quality Control Requirements
The monograph outlines several mandatory tests that assess both physical integrity and chemical uniformity: European Pharmacopoeia - Background and Mission
Understanding Ph. Eur. Monograph 0478: The Standard for Tablets
In the pharmaceutical world, the European Pharmacopoeia (Ph. Eur.) is the gold standard for quality control, and Monograph 0478 is the essential blueprint for anyone manufacturing or testing oral tablets. This general monograph defines exactly what a tablet is and sets the baseline requirements for its production and performance. What is Monograph 0478?
Ph. Eur. 0478 covers solid preparations each containing a single dose of one or more active substances. While it primarily addresses oral tablets, it excludes certain forms like lozenges or oral pastes, which have their own specific standards. Key Quality & Performance Tests
The monograph outlines several critical tests to ensure every batch is safe and effective:
Uniformity of Dosage Units (2.9.40): This ensures each tablet contains the correct amount of active ingredient. It often involves testing for Uniformity of Mass or Content.
Disintegration (2.9.1): This measures how quickly a tablet breaks down in liquid. Standard uncoated tablets must typically disintegrate within 15 minutes in water, while film-coated tablets are allowed up to 30 minutes.
Dissolution (2.9.3): A mandatory test (unless otherwise justified) to confirm the active substance is released at the right rate and time.
Subdivision of Tablets: If a tablet has a break-mark for dose splitting, the monograph requires a specific test for the Uniformity of Mass of the subdivided parts to ensure patients get the correct fractional dose. Why It Matters
Following Ph. Eur. standards is legally binding for marketing medicines in signatory states. It provides the scientific basis for quality control throughout a product's life cycle—from development to final distribution.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Revised Ph. Eur. Chapter Tablets - ECA Academy
The European Pharmacopoeia (Ph. Eur.) general monograph for Tablets (0478) establishes mandatory quality standards and manufacturing requirements for all tablet dosage forms marketed in Europe. It is maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Scope and Definition
Monograph 0478 defines tablets as solid pharmaceutical dosage forms containing a single dose of one or more active substances. They are typically obtained by compressing uniform volumes of particles and are intended for oral administration, though some sub-types may be intended for other routes. Core Quality Requirements
According to the current Ph. Eur. standards, tablets must meet several critical physical and chemical specifications: Test methods The monograph specifies the test methods
Uniformity of Dosage Units: Ensures each tablet contains the correct amount of active ingredient. This is generally verified through Uniformity of Mass or Uniformity of Content.
Disintegration: Measures the time required for a tablet to break up into smaller particles in a liquid medium. Uncoated tablets typically must disintegrate within 15 minutes, while coated tablets may have longer allowances.
Dissolution: A test to determine how the active substance is released into a solvent over time, ensuring the drug will be available for absorption in the body. Mechanical Strength:
Resistance to Crushing: Often called "hardness," it measures the force needed to break the tablet.
Friability: Assesses the tablet's ability to withstand abrasion during packaging and transport. The standard limit is generally not more than 1.0% mass loss. Specific Tablet Categories
Monograph 0478 also provides additional requirements for specialized tablet types:
Uncoated and Coated Tablets: Differing primarily in disintegration time and surface finish.
Effervescent Tablets: Designed to dissolve in water with the release of carbon dioxide.
Orodispersible Tablets: Tablets that disperse rapidly in the mouth before swallowing.
Modified-release Tablets: Including prolonged-release and delayed-release (gastro-resistant) forms to control where or when the drug is absorbed. Reference Standards
For laboratory testing and validation of specific monographs, researchers use International Chemical Reference Substances (ICRS) provided by the EDQM to ensure analytical accuracy in assays and identity tests.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
Monograph 0478 imposes stricter criteria for non-standard tablets.
While the global industry tries to harmonize via the ICH Q4B process, differences remain.
| Parameter | Ph. Eur. 0478 | USP <701>/<711> | JP (General Tests) | | :--- | :--- | :--- | :--- | | Disintegration time (uncoated) | 15 min | 15 min (but often 30 min for large tabs) | 15 min | | Dissolution vessel volume | 900 mL (preferred) | 500, 900, or 1000 mL | 900 mL | | Friability acceptance | 1.0% (uncoated) | 1.0% (but 0.8% for high-use) | 1.0% | | Uniformity of dosage units | AV ≤ 15.0 (2.9.40) | AV ≤ 15.0 (identical via ICH Q4B) | AV ≤ 15.0 |
Critical difference: Ph. Eur. 0478 allows a "re-test" for disintegration (repeat on 6 new tablets) if 1-2 of the first 6 fail. USP <701> requires that if 1-2 fail, you test 12 more; if more than 2 fail initially, rejection is immediate.
The container label must include (per Ph. Eur. general notices and individual monograph):
In the landscape of pharmaceutical quality control, few documents carry as much authoritative weight as the monographs of the European Pharmacopoeia (Ph. Eur.). For manufacturers seeking to market oral solid dosage forms within the 38 member states of the European Pharmacopoeia Convention (and beyond, via the CE marking or WHO prequalification), compliance is non-negotiable.
At the heart of oral solid dosage regulation lies Monograph 0478: Tablets. While it may seem like a generic entry, Monograph 0478 is the foundational legal text defining what a tablet is, how it must behave, and the tests it must pass before it is deemed safe for human use. Unlike active substance monographs (e.g., Paracetamol or Aspirin), this is a general monograph. It applies to all tablet formulations unless specifically waived or modified by an individual product monograph.
This article provides an exhaustive technical breakdown of Ph. Eur. 0478, covering its scope, analytical requirements (disintegration, dissolution, uniformity), official interpretation, and common pitfalls in Quality Control (QC) laboratories.
The monograph sets GMP-related principles for manufacture:
Conclusion: Master Ph. Eur. 0478, and you master tablet quality control. Overlook its nuance, and you risk the entire European market.
Disclaimer: This article is for informational purposes and does not substitute for consulting the official European Pharmacopoeia (current edition). Always refer to the legally binding Ph. Eur. text for specific acceptance criteria and validation requirements.